Compare Asana Inc. (ASAN) vs 10X Genomics Inc (TXG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Asana Inc. vs 10X Genomics Inc — how do they compare? Asana Inc. trades at $8.91 (market cap $2.13B), while 10X Genomics Inc trades at $58.03 (market cap $7.61B). The key difference: 10X Genomics Inc is far larger — about 3.6× Asana Inc.'s market cap, and 10X Genomics Inc is trading nearer its 52-week high, Asana Inc. nearer its low. Which is the better fit depends on your goals.
| ASAN | TXG | |
|---|---|---|
Market Cap | $2.13B | $7.61B |
Sector | Consumer Cyclical | Health |
52-Week High | $15.19 | $58.57 |
52-Week Low | $5.46 | $11.34 |
Enterprise Value | $1.96B | $7.14B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Asana (ASAN) trades at $9.23, down slightly by 0.32% today. The stock exhibits a bullish technical trend with strong moving average signals, though oscillators indicate overbought conditions. Fundamentally, revenue growth is robust with fiscal 2025 revenue reaching $723.88 million, but the company remains unprofitable with a net loss of $255.54 million. Recent news highlights AI product innovation and a strategic partnership with Norway's sovereign wealth fund, signaling positive business momentum.
The outlook for Asana is mixed. Analyst consensus leans bullish with a $10.33 price target, but persistent losses and intense competition from tech giants pose significant risks. Upside potential hinges on continued revenue growth and path to profitability, while downside risks include margin pressure and execution challenges in a competitive SaaS market.
TXG trades at $58.57, up 12.57% in 24 hours, reflecting strong momentum. The stock is technically bullish with moving averages supporting the uptrend, though RSI levels suggest overbought conditions. Fundamentally, the company shows improving trends with Q2 2026 earnings beating estimates and revenue growth, yet remains unprofitable with a negative net income margin. Recent news highlights collaborations and acquisitions expanding its genomic capabilities.
Outlook is mixed; analyst consensus is neutral with a $46 price target below current levels, indicating caution despite recent beats. Key risks include sustained losses and competitive pressures, but operational cash flow growth and strategic expansions offer potential upside for patient investors focused on long-term biotech innovation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Asana Inc.
Asana Inc is a software company. The company provides a platform for work management that helps teams orchestrate work, from daily tasks to cross-functional strategic initiatives. It helps plan marketing campaigns, streamlines processes, manages sales, and manage product launches. Also, the company provides project management and workflow management solutions.
Read more on ASAN →About 10X Genomics Inc
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →
